Measurement of serotonin transporter binding with PET and [11C]MADAM: A test–retest reproducibility study
暂无分享,去创建一个
[1] J. Marcusson,et al. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.
[2] M Slifstein,et al. Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] Sylvain Houle,et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.
[4] C. Halldin,et al. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Denis Guilloteau,et al. Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter , 2001 .
[6] A Frazer,et al. Effects of Chronic Antidepressant Treatments on Serotonin Transporter Function, Density, and mRNA Level , 1999, The Journal of Neuroscience.
[7] Alan A. Wilson,et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.
[8] J. Hirvonen,et al. Measurement of Cortical Dopamine D1 Receptor Binding with [11C]SCH 23390: A Test–Retest Analysis , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] K. Fite,et al. Diurnal variation in serotonin immunoreactivity in the dorsal raphe nucleus , 2005, Brain Research.
[10] S. Horschitz,et al. Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor , 2001, Neuroreport.
[11] Sylvain Houle,et al. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.
[12] Marc Laruelle,et al. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.
[13] J. Palacios,et al. Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.
[14] Denis Guilloteau,et al. [11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET , 2005, Synapse.
[15] C. Halldin,et al. Selectivity of 3H‐MADAM binding to 5‐hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects , 2004, British journal of pharmacology.
[16] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[17] A. Heinz,et al. DASB –in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer , 2004, Journal of neurochemistry.
[18] J. Hirvonen,et al. Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride , 2003, Nuclear medicine communications.
[19] Alan A. Wilson,et al. Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] S. Laughlin,et al. An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] Denis Guilloteau,et al. Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[22] C. Halldin,et al. Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain , 2003, Psychopharmacology.
[23] G. Halliday,et al. Cytoarchitecture of the human dorsal raphe nucleus , 1990, The Journal of comparative neurology.
[24] W. Abramowitz,et al. Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. , 2000, Clinical therapeutics.
[25] G. Sedvall,et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.
[26] L. Farde,et al. PET analysis of central [11 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effects , 1992 .
[27] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[28] K Wienhard,et al. The ECAT EXACT HR: Performance of a New High Resolution Positron Scanner , 1994, Journal of computer assisted tomography.
[29] T. Greitz,et al. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.
[30] Sylvain Houle,et al. Effects of Tryptophan Depletion on the Serotonin Transporter in Healthy Humans , 2005, Biological Psychiatry.
[31] N. Rojansky,et al. Influence of age, sex and diurnal variability on imipramine receptor binding and serotonin uptake in platelets of normal subjects. , 1991, Journal of psychiatric research.
[32] Guy Marchal,et al. Automated multi-moda lity image registration based on information theory , 1995 .